Oryzon Genomics Investor Call to Discuss Positive FDA Feedback on End-of-Phase II Meeting and Plans for PORTICO-2 Phase III Trial with Vafidemstat in Borderline Personality Disorder
| DATE: | October 1, 2024 |
|---|---|
| TIME: | 9:00 AM EDT |
| LOCATION: | Virtual |
About The Event
Join Oryzon Genomics for a virtual investor call to discuss positive feedback from a recent End-of-Phase II meeting for vafidemstat in Borderline Personality Disorder (BPD) with the US Food and Drug Administration (FDA). Company management will also discuss the clinical trial design and initiation plans for the PORTICO-2 Phase III study.
A live question and answer session will follow the formal presentation.